DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia

Early Phase 1

Completed

Conditions: Hyperglycemia

Interventions: Drug: Insulin

First Posted Date: 2019-04-05

Last Posted Date: 2023-01-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 9

Registration Number: NCT03904199

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Hormone Receptor Positive Tumor

Interventions: Drug: Durvalumab
Drug: Anastrozole 1mg
Drug: Letrozole 2.5mg
Drug: Exemestane 25 MG

First Posted Date: 2019-03-14

Last Posted Date: 2022-05-31

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 17

Registration Number: NCT03874325

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Florida Pancreas Collaborative Next Generation Biobank

Active, not recruiting

Conditions: Cancer Cachexia
Pancreatic Cancer

Interventions: Other: Blood Sample Collection
Other: Tumor Sample collection
Other: Data Collection

First Posted Date: 2019-02-22

Last Posted Date: 2025-05-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 500

Registration Number: NCT03851133

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center & Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of Florida - Orlando, Orlando, Florida, United States

and more 11 locations

Emotional Support Messages Following a Cancer Diagnosis

Completed

Conditions: Psychological Stress
Anxiety

Interventions: Behavioral: Questionnaire 1a
Behavioral: Questionnaire 1b
Behavioral: Questionnaire 2a
Behavioral: Questionnaire 2b
Behavioral: Questionnaire 3a
Behavioral: Questionnaire 3b
Behavioral: Questionnaire 4a
Behavioral: Questionnaire 4b

First Posted Date: 2019-02-15

Last Posted Date: 2020-11-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 417

Registration Number: NCT03840109

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: CC-122
Drug: Nivolumab

First Posted Date: 2019-02-08

Last Posted Date: 2022-10-05

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 23

Registration Number: NCT03834623

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Brain Metastases

Interventions: Drug: Nivolumab
Radiation: Stereotactic Radiosurgery

First Posted Date: 2019-01-17

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 14

Registration Number: NCT03807765

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Minnelide

First Posted Date: 2018-11-30

Last Posted Date: 2025-03-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT03760523

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Phase 1

Completed

Conditions: Metastatic Cancer
Recurrent Cancer
Solid Tumor
Renal Cell Carcinoma
Urothelial Carcinoma
NSCLC
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: IRX 2
Drug: Nivolumab

First Posted Date: 2018-11-29

Last Posted Date: 2023-04-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 12

Registration Number: NCT03758781

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer

Not Applicable

Withdrawn

Conditions: Prostate Cancer

Interventions: Device: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2018-11-21

Last Posted Date: 2020-05-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT03748719

Development of a Mindfulness-Based Treatment for the Reduction of Alcohol Use and Smoking Cessation

Not Applicable

Completed

Conditions: Alcohol Use, Unspecified
Tobacco Use

Interventions: Behavioral: Mindfulness Based Relapse Prevention - Smoking and Alcohol
Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2018-11-08

Last Posted Date: 2023-06-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 67

Registration Number: NCT03734666

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy